tj011133
mAbexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started May 8, 2019 (NCT03934814)
Timeline
Indications
Mechanism of action
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650520 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05709093 | Phase 3 | Mar 30, 2023 | I-Mab Biopharma |
| NCT05148533 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2021 | I-Mab Biopharma |
| NCT04895410 | Phase 1 | Sep 13, 2021 | AbbVie |
| NCT04912063 | Phase 1 | Jun 25, 2021 | AbbVie |
| NCT04202003 | Phase 1/Phase 2 (Phase 2) | Dec 27, 2019 | I-Mab Biopharma |
| NCT03934814 | Phase 1 | May 8, 2019 | I-Mab Biopharma |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| I-Mab Biopharma | For profit | 4 | 4 | 3 | 2019 |
| AbbVie | For profit | 2 | 2 | 1 | 2021 |
2 organizations
Page 1 / 1